Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Ioanna
Ioanna Chinou, Pagagou GR
| Patent application number | Description | Published |
|---|---|---|
| 20110034427 | Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives - Quercetin, 18 α-glycyrrhetinic and/or hederagenin and/or their derivatives are used as anti-aging and/or whitening agents for the topical treatment of skin. Methods for testing the anti-aging and whitening properties of these compounds are disclosed. | 02-10-2011 |
Ioanna Georgopoulou, Thessaloniki GR
| Patent application number | Description | Published |
|---|---|---|
| 20100094055 | PROCESS FOR THE PREPARATION OF PHENETHYLAMINE DERIVATIVES - The present invention relates to an improved process for the preparation of essentially pure Venlafaxine Hydrochloride. Particularly, the process for the preparation of Venlafaxine Hydrochloride comprises the following steps: i) Preparation of 1-[Cyano-1-(4-methoxyphenyl)methyl]cyclohexanol, ii) Preparation of crude Venlafaxine Hydrochloride by reduction of 1-[Cyano-1-(4-methoxyphenyl)methyl]cyclohexanol with Alkali metal borohydride and Lewis acid and subsequent conversion to Venalfaxine hydrochloride with formic acid and paraformaldehyde and finally iii) Purification of crude Venlafaxine Hydrochloride. | 04-15-2010 |
Ioanna Koutri, Pallini Attikis GR
| Patent application number | Description | Published |
|---|---|---|
| 20100297225 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING AN ANTIMUSCARINIC AGENT AND A WETTING AGENT AS WELL AS A PROCESS FOR THE PREPARATION THEREOF - The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a wetting agent, such as Sodium Docusate to improve the release of the active ingredient and a method for the preparation thereof. | 11-25-2010 |
| 20110033538 | Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof - The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation. | 02-10-2011 |
Ioanna Skountzou, Atlanta, GA US
| Patent application number | Description | Published |
|---|---|---|
| 20100330190 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF - Embodiments of the disclosure encompass compositions and methods for generating immune responses in an animal or human host. Embodiments of the compositions encompass proteins derived from the surface proteins of bacteria and protozoa, and in particular the flagellum component flagellin, and which have adjunctival properties when administered in conjunction with an immunogen. Embodiments of the compositions of the disclosure are modified to incorporate a heterologous transmembrane-cytoplasmic domain allowing the peptides to be incorporated into virus-like particles. Embodiments of the methods of generating an immunological response in an animal or human comprise exposing the immune system of an animal or human host to an immunogen and a virus-like particle comprising an adjuvant polypeptide including a host cell Toll-like receptor ligand polypeptide having a transmembrane-cytoplasmic tail polypeptide, and a heterologous signal peptide. | 12-30-2010 |
Ioanna Stamati, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20120070377 | COMPOUNDS AND BIOLOGICAL MATERIALS AND USES THEREOF - The invention provides compounds of Formula (I): wherein b, D, R | 03-22-2012 |
Ioanna Stergiades, San Francisco, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090023777 | Substituted 4-amino-benzylpiperidine compounds - This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds. | 01-22-2009 |
| 20090023934 | Process for preparing an intermediate to opioid receptor antagonists - The invention provides an efficient method for preparing 3-endo-(8-azabicyclo[3.2.1]oct-3-yl)benzamide by hydrogenation, under controlled conditions, of an amino-protected 3-(8-azabicyclo[3.2.1 ]oct-2-en-3-yl)benzamide intermediate in which the amino-protecting group is removable by catalytic hydrogenation. | 01-22-2009 |
| 20100035921 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS - The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): | 02-11-2010 |
| 20100125150 | CRYSTALLINE FORM OF A BETA2 ADRENERGIC RECEPTOR AGONIST - The invention provides a novel β | 05-20-2010 |
| 20110166355 | PROCESS FOR PREPARING AN INTERMEDIATE TO MU OPIOID RECEPTOR ANTAGONISTS - The invention provides an efficient method for preparing 3-endo-(8-azabicyclo[3.2.1]oct-3-yl)benzamide by hydrogenation, under controlled conditions, of an amino-protected 3-(8-azabicyclo[3.2.1]oct-2-en-3-yl)benzamide intermediate in which the amino-protecting group is removable by catalytic hydrogenation. | 07-07-2011 |